Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

A new drug is helping families who've spent years padlocking fridges, chaining garbage cans, and hiding food as their ...

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds. On June 23, TD ...

Soleno Therapeutics (NASDAQ:SLNO) traded higher on Tuesday after Betaville said in a report that the Redwood City, California ...

Vykat XR may also change the levels of other medicines in the body. If you are taking any of these other medicines, your health care provider may make changes to your doses or medicines.

VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to U.S. patients.

VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS). IMPORTANT SAFETY INFORMATION.

Announced U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and ...

Vykat has had a circuitous route to approval - in June 2020, Soleno announced that its 12-patient, Phase 3 clinical study DESTINY PWS had failed to meet its primary endpoint of change from ...

Vykat XR is supplied as an extended-release tablet in 25mg, 75mg, and 150mg dosage strengths. Prior to initiating treatment, fasting plasma glucose and HbA1c should be tested; ...

Announced U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and ...